Beijing News (Reporter Zhang Zhaohui) On October 13, Fosun Pharma issued an announcement saying that recently, the company’s holding subsidiary Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. Alvatropolate acid tablets have been approved for clinical trials for the indications of chronic immune thrombocytopenia (ITP) in adults. Fosun Pharmaceutical Industry intends to carry out a phase III clinical trial of this drug for this indication in China when conditions are met in the near future.
As of now, avatropol maleate tablets for chronic liver disease-related thrombocytopenia suitable for elective diagnostic procedures or surgery in adult patients have been marketed in the United States, the European Union, and China, and are suitable for chronic immune thrombocytopenia ( ITP) Alvatropol maleate tablets have been marketed in the United States.
In addition, the use of avatropol maleate tablets for tumor chemotherapy-induced thrombocytopenia (CIT) has also recently completed an international multicenter phase III clinical trial, and the preliminary analysis results did not reach the preset primary composite endpoint. Fosun Pharmaceutical Industry will combine the analysis of the clinical research trials and results to further evaluate and determine the clinical development strategy of the indication in China, optimize the clinical trial design and determine the registration strategy.
In March 2018, Fosun Pharmaceutical Industry obtained the exclusive sales agency license of AkaRx, Inc. (hereinafter referred to as “AkaRx”) in the Mainland of China and Hong Kong Special Administrative Region of AkaRx, Inc. (hereinafter referred to as “AkaRx”). AkaRx remains the The right holder of the medicine in the region is also responsible for the supply.
The latest data from IQVIA MIDAS shows that in 2019, the global sales of avatropol maleate tablets were approximately US$3.43 million. As of September 2020, Fosun Pharma has invested approximately RMB 106 million in research and development.
Proofreading Li Xiangling